Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for SHR-2173 in Primary Membranous Nephropathy

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...

Company Drug

J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse

Fineline Cube Jul 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...

Company Drug

Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants

Fineline Cube Jul 9, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic...

Company Drug

Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment

Fineline Cube Jul 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Policy / Regulatory

NMPA Updates Review Procedures for Conditional Drug Marketing Approval Applications

Fineline Cube Jul 9, 2025

The National Medical Products Administration (NMPA) this week released a revised draft proposal for the...

Company Medical Device

Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation

Fineline Cube Jul 9, 2025

US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for...

Company Drug

HutchMed Announces First Commercial Shipments of Tazverik Across China

Fineline Cube Jul 9, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...

Company Deals Medical Device

Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion

Fineline Cube Jul 8, 2025

Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...

Company Drug

RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma

Fineline Cube Jul 8, 2025

RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) in China has...

Company Drug

Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC

Fineline Cube Jul 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...

Company Drug

Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema

Fineline Cube Jul 8, 2025

German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...

Company Deals

GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha

Fineline Cube Jul 8, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...

Company Deals

Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence

Fineline Cube Jul 8, 2025

China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....

Policy / Regulatory

NMPA Releases 93rd Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 8, 2025

The National Medical Products Administration (NMPA) has released the 93rd batch of reference drugs for...

Company Deals Drug

Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases

Fineline Cube Jul 8, 2025

Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...

Company Deals

CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK

Fineline Cube Jul 8, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...

Company Drug

Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer

Fineline Cube Jul 8, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Drug

Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis

Fineline Cube Jul 8, 2025

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...

Policy / Regulatory

China’s CDE Announces 95th Batch of Reference Preparations for Public Comment

Fineline Cube Jul 7, 2025

China’s Center for Drug Evaluation (CDE) has released the 95th batch of reference preparations for...

Policy / Regulatory

China Ministry of Finance Restricts EU-Imported Medical Devices in Government Procurement Over RMB45 Million

Fineline Cube Jul 7, 2025

China’s Ministry of Finance (MoF) has issued the “Notice on Implementing Relevant Measures for EU-Imported...

Posts pagination

1 … 178 179 180 … 713

Recent updates

  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
  • Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
  • Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
  • Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.